Arthritis & Rheumatology · 2024 · 20 citations · 28 references
PharmacyPharmacologyPharmacotherapyCardiovascular PharmacotherapyClinical PharmacologyRenal PharmacotherapyCardiovascular Disease PreventionCardiovascular Drug SafetyEfficacy EvaluationRenal PharmacologySodium-glucose Cotransporter 2 InhibitorsSystemic Lupus ErythematosusCardiorenal SyndromeComparative Clinical TrialsSodium-glucose CotransportSodium-glucose Cotransporter 2 InhibitionSystemic Lupus Erythematosus AssociationsType 2 Diabetes Comorbidity ManagementType 2 Diabetes Treatment
OBJECTIVE: Patients with systemic lupus erythematosus (SLE) were excluded from sodium-glucose cotransporter 2 inhibitors (SGLT2i) clinical trials. It is unknown whether the cardiorenal benefits of SGLT2i extend to patients with SLE and comorbid type 2 diabetes (T2D). METHODS: We performed an emulated clinical trial in an insurance-based cohort in the United States, evaluating SGLT2i versus dipeptidyl peptidase-4 inhibitors (DPP4i) for primary prevention of cardiovascular, renal, and other clinical outcomes among patients with both SLE and comorbid T2D. SGLT2i initiators were matched to DPP4i initiators using propensity scores (PSs) based on clinical and demographic factors. Hazard ratios (HRs) with 95% confidence intervals (CIs) were calculated using Cox models. RESULTS: Outcomes among 2,165 patients starting SGLT2i and 2,165 PS-matched patients starting DPP4i were compared. Over 753.1 (±479.2) mean days, SGLT2i recipients had significantly lower risks of incident acute kidney injury (HR 0.49, 95% CI 0.39-0.63), chronic kidney disease (HR 0.61, 95% CI 0.50-0.76), end-stage renal disease (HR 0.40, 95% CI 0.20-0.80), heart failure (HR 0.72, 95% CI 0.56-0.92), emergency department visits (HR 0.90, 0.82-0.99), and severe sepsis (HR 0.61, 95% CI 0.39-0.94). Risks of all-cause mortality (HR 0.89, 95% CI 0.65-1.21), lupus nephritis (HR 0.67, 95% CI 0.38-1.15), myocardial infarction (HR 0.81, 95% CI 0.54-1.23), stroke (HR 1.03, 95% CI 0.74-1.44), and hospitalizations (HR 0.76, 95% CI 0.51-1.12) did not differ. Genital infection risk (HR 1.31, 95% CI 1.07-1.61) was increased, but urinary tract infection risk (HR 0.90, 95% CI 0.79-1.03) did not differ. No significant difference was observed for diabetic ketoacidosis risk (HR 1.07, 95% CI 0.53-2.14) and fractures (HR 0.95, 95% CI 0.66-1.36). CONCLUSION: In this emulated clinical trial, treatment with SGLT2i, compared to DPP4i therapy, was associated with significantly reduced risks of several cardiorenal complications among patients with both SLE and T2D.
28
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
Bernard Zinman, Christoph Wanner, John M. Lachin et al. · New England Journal of Medicine · 2015 · 12K citations · Full text
Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes
Bruce Neal, Vlado Perkovic, Kenneth W. Mahaffey et al. · New England Journal of Medicine · 2017 · 7.8K citations · Full text
Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes
Stephen D. Wiviott, Itamar Raz, Marc P. Bonaca et al. · New England Journal of Medicine · 2018 · 6.3K citations · Full text
Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy
Vlado Perkovic, Meg Jardine, Bruce Neal et al. · New England Journal of Medicine · 2019 · 6K citations · Full text
Medicine, Nephrology, Pharmacology +17
Dapagliflozin in Patients with Chronic Kidney Disease
Hiddo J.L. Heerspink, Bergur V. Stefánsson, Ricardo Correa‐Rotter et al. · New England Journal of Medicine · 2020 · 5.2K citations · Full text